参考文献: [1]CAR T-cell therapy for solid tumors. Lancet Oncol 2021; DOI: 10.1016/S1470-2045(21)00353-3. [2]https://endpts.com/exclusive-carl-junes-tmunity-encounters-a-lethal-roadblock-as-2-patient-deaths-derail-lead-trial-raise-red-flag-forcing-a-rethink-of-car-t-for-solid-tumor...
CAR-T cell performance: how to improve their persistence? Front. Immunol. 13, 878209 (2022). CAS PubMed PubMed Central Google Scholar Drougkas, K. et al. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end? J. Cancer Res...
参考文献: [1]CAR T-cell therapy for solid tumors. Lancet Oncol 2021; DOI: 10.1016/S1470-2045(21)00353-3. [2]https://endpts.com/exclusive-carl-junes-tmunity-encounters-a-lethal-roadblock-as-2-patient-deaths-derail-lead-trial-...
Developing a CAR T cell therapy for solid tumors is particularly challenging because the therapy needs to first reach the solid tumor and then survive in a harsh microenvironment that is filled with cancer cells and other cells that prevent attack by the CART cells. But Priceman and his team h...
CARs are recombinant receptors for cell surface antigen redirected the specificity and activity of blood T lymphocytes and other types of the immune cells [2]. The rapid establishment of tumor-targeted T cells, elimination of obstacles, and augmentative kinetics of active immunization are noticed as...
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the “next generation” of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment surround
CAR-T疗法就是嵌合抗原受体T细胞免疫疗法，是一种治疗肿瘤的新型精准靶向疗法。通过基因工程技术将T细胞...
The Next Frontier of CAR T-Cell Therapy: Solid Tumors Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas,” Clin Cancer Res, 5:985–90, 1999. C.E. Brown et al., “Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T ...
1)The Next Frontier of CAR T-Cell Therapy: Solid Tumors 2)Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas,” Clin Cancer Res, 5:985–90, 1999. 3)C.E. Brown et al., “Bioactivity ...
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the “next generation” of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment surround